

해외 바이오의약품 임상 현황 ('24년 1월 2주)

한국바이오의약품협회, 2024.01.16.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2024.01.08.~2024.01.14.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 11건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06027879	Anti-viral T-cell Therapy by Gamma Capture	Biological: Specific T- Lymphocytes	Paul Szabolcs University of Pittsburgh	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06027879
NCT05828511	A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment.	Drug: Linvoseltamab	Regeneron Pharmaceuticals	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05828511
NCT06173895	A Relative Bioavailability Study of LY3454738 in Healthy Participants	Drug: LY3454738	Eli Lilly and Company	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06173895
NCT06046820	The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency	Drug: INZ-701 Drug: Control Arm (Conventional Therapy)	Inozyme Pharma	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06046820
NCT06043323	A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma	Drug: Axicabtagene Ciloleucel Drug: Cyclophosphamide Drug: Fludarabine phosphate Drug: Prednisone Drug: Diphenhydramine Drug: Acetaminophen	M.D. Anderson Cancer Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06043323
NCT06028932	A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients	Drug: Sacituzumab govitecan	Yale University Gilead Sciences	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06028932
NCT05911997	MTC Versus FMT in for RCDI	Drug: MTC 01 Drug: Fecal Microbiota Transplantation (FMT)	Icahn School of Medicine at Mount Sinai National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05911997
NCT05995353	A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease	Drug: Risankizumab	AbbVie	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05995353
NCT05954871	Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer	Drug: GDC-1971 Drug: Osimertinib Drug: Cetuximab	Genentech, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05954871
NCT06033196	Tocilizumab in Lung Transplantation	Drug: Tocilizumab Drug: Placebo for Tocilizumab	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06033196
NCT06147037	A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours	Drug: FPI-2053 Drug: [111In]-FPI-2107 Drug: [225Ac]-FPI-2068	Fusion Pharmaceuticals Inc. AstraZeneca	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06147037

해외 바이오의약품 임상 현황 ('24년 1월 2주)

한국바이오의약품협회, 2024.01.16.

○ 중국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06161909	Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection	Drug: sintilimab	Fujian Medical University Union Hospital	Phase 3	